Company Announcements
Story Highlights
- Edesa Biotech advances its vitiligo treatment with EB06, preparing for a Phase 2 study.
- A $15 million equity financing strengthens Edesa’s financial position despite a net loss.
- Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks’ Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts’ recommendations with Your Smart Portfolio
Edesa Biotech ( (EDSA) ) has issued an announcement.
Edesa Biotech reported its fiscal first-quarter results for 2025, highlighting progress in its vitiligo treatment program with its leading candidate, EB06, as they prepare for an IND application for a Phase 2 study. The company’s financial position was strengthened by a $15 million equity financing, allowing them to advance the vitiligo program and sustain current operations, despite reporting a net loss of $1.6 million for the quarter.
More about Edesa Biotech
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company that focuses on developing host-directed therapeutics for treating immuno-inflammatory diseases. The company’s clinical pipeline is concentrated on medical dermatology and related immune conditions.
YTD Price Performance: 71.05%
Average Trading Volume: 1,950,775
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $11.27M
For a thorough assessment of EDSA stock, go to TipRanks’ Stock Analysis page.
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
